Estrella Immunopharma Experiences Significant Drop in Short Interest

Estrella Immunopharma, Inc. (NASDAQ:ESLA) reported a substantial decline in short interest as of February 13, 2023. The short interest fell to 725,979 shares, marking a decrease of 23.1% from the previous total of 943,482 shares recorded on January 29, 2023. Currently, approximately 4.3% of the company’s shares are short sold, reflecting a shift in investor sentiment.

The average daily trading volume for Estrella Immunopharma stands at 733,653 shares, resulting in a days-to-cover ratio of 1.0 days. This metric indicates the number of days it would take for all short positions to be covered based on the average trading volume.

Market Performance and Investor Activity

During midday trading on February 14, 2023, shares of Estrella Immunopharma decreased by $0.03 to reach $1.11. A total of 9,183 shares changed hands, significantly lower than its average trading volume of 234,080 shares. The company’s stock has seen a 12-month low of $0.73 and a high of $3.15, with a market capitalization of approximately $41.93 million. The price-to-earnings ratio currently stands at -3.27, and the stock has a beta of 0.53, indicating lower volatility compared to the market.

Recent activity among institutional investors has influenced the stock’s performance. Notably, Renaissance Technologies LLC increased its holdings in Estrella Immunopharma by an impressive 1,045.7% during the fourth quarter. This increase brought Renaissance’s total ownership to 122,468 shares, valued at $191,000 after acquiring an additional 111,779 shares.

Other institutional movements include Geode Capital Management LLC, which raised its position by 8.2%, acquiring 8,318 shares to reach a total of 109,808 shares valued at $171,000. Additionally, Marshall Wace LLP entered the market with a new stake valued at around $88,000. XTX Topco Ltd also made a significant move, increasing its holdings by 376.9% to own 49,472 shares worth $77,000. Finally, State Street Corp lifted its stake by 93.5%, now owning 43,252 shares valued at $67,000.

Currently, institutional investors and hedge funds hold approximately 0.35% of Estrella Immunopharma’s stock.

Company Profile and Future Outlook

Estrella Immunopharma is a preclinical-stage biopharmaceutical company focused on developing T-cell therapies aimed at treating blood cancers and solid tumors in the United States. The company’s lead product candidates include EB103, targeting diffuse large B-cell lymphoma, and EB104, which aims to address both diffuse large B-cell lymphoma and acute lymphocytic leukemia.

In collaboration with Imugene Limited, Estrella Immunopharma is also working on treatments for solid tumors using Imugene’s product candidate CF33-CD19t alongside EB103. This partnership underscores the company’s commitment to advancing innovative cancer therapies.

As Estrella Immunopharma navigates the complexities of the biopharmaceutical landscape, the recent decline in short interest may reflect a growing confidence among investors in the company’s future prospects. With ongoing developments in its pipeline, stakeholders will be keen to monitor the company’s progress in bringing its therapies to market.